
Kura Oncology, Inc. (NASDAQ:KURA) shareholders (or potential shareholders) will be happy to see that the Chairman, Troy Wilson, recently bought a whopping US$1.5m worth of stock, at a price of US$7.52. Not only is that a big swing, but it increased their holding size by 16%, which is definitely great to see.
In fact, the recent purchase by Troy Wilson was the biggest purchase of Kura Oncology shares made by an insider individual in the last twelve months, according to our records. That means that an insider was happy to buy shares at above the current price of US$7.49. Their view may have changed since then, but at least it shows they felt optimistic at the time. We always take careful note of the price insiders pay when purchasing shares. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. Troy Wilson was the only individual insider to buy during the last year.
Troy Wilson bought 400.00k shares over the last 12 months at an average price of US$9.64. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
See our latest analysis for Kura Oncology
Kura Oncology is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.
For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Kura Oncology insiders own about US$10m worth of shares. That equates to 1.5% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
It's certainly positive to see the recent insider purchase. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. When combined with notable insider ownership, these factors suggest Kura Oncology insiders are well aligned, and that they may think the share price is too low. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Every company has risks, and we've spotted 2 warning signs for Kura Oncology you should know about.
Of course Kura Oncology may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.